All In Biotech

Drug Trial Radar · NCT07608770

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

A Phase 2b, Randomized, Placebo-Controlled Study With Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (Stage 1)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Apr 2027

Study completion Nov 2027

Sponsor

Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat

Conditions

  • Subcutaneous Fat

Interventions

  • CBL-514 InjectionDrug

    Provided as a ready for use injectable CBL-514 solution

  • 0.9% Sodium ChlorideDrug

    Injectable 0.9% Sodium Chloride solution as placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from Baseline in abdominal fat in the CBL-514 group versus the placebo groupTime frame: From baseline to 4 weeks after final treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site 1

    South Yarra, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.